Endocare CE-marks prostatic stent:
This article was originally published in Clinica
Executive Summary
Endocare has CE-marked its Horizon prostatic stent for treating benign prostatic hyperplasia, a condition in which the patient's prostate is enlarged causing obstruction to the bladder. The nitinol stent expands and opens the prostatic urethra, providing immediate relief for up to 30 days.